Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ficerafusp alfa + Pembrolizumab in 1L PD-L1+ Recurrent/Metastatic HNSCC
NCT06788990Phase 3Recruiting
- Sponsor
- Bicara Therapeutics
- Start
- Jan 2025
- Primary completion
- Apr 2028
- Modality
- Prophylactic Vaccines, Bispecific Antibodies, Therapeutic Vaccines
- Countries
- 28
01
Overview
Phase 3, randomised, double-blind trial of ficerafusp alfa in head and neck squamous cell carcinoma (HNSCC) (5 arms), sponsored by Bicara Therapeutics. Primary endpoints: Treatment-Emergent Adverse Events, Objective Response Rate at 3 years and 1 more. Started Jan 2025; status: recruiting.
02
Drugs
ficerafusp alfa
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT06788990.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06788990.